Inside Drug Pricing - 06/29/2020

HHS Sets Aside $500M For Convalescent Plasma As FDA Considers EUA

By John Wilkerson, Beth Wang / June 24, 2020 at 3:02 PM
HHS on Monday (June 22) paid another $102 million for convalescent plasma out of $500 million that’s been set aside for the blood product, and FDA Commissioner Stephen Hahn said the agency is considering authorizing emergency use of the product to treat COVID-19 patients. The Mayo Clinic this week released promising preliminary results from a study of 20,000 patients treated with the plasma. Convalescent plasma is made from blood donated by patients who recently recovered from COVID-19. The plasma is...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.